Reprogramming immune cells to fight brain cancer
Official title: Targeting macrophage reprogramming in glioblastoma
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11126127 · Data updated 2026-11-12
This study is looking at how to change certain immune cells in the brain that usually help glioblastoma grow, so they can instead help fight the cancer, focusing on a specific receptor called GPR183, with the hope of finding better treatments for patients with this tough-to-treat brain cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $390,937 |
| NIH project number | 7R01NS127824-02 |
| Project ID | NIH-11126127 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking new treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer with a poor prognosis. It aims to understand how certain immune cells, specifically tumor-associated macrophages, can be reprogrammed from promoting tumor growth to fighting against it. The study will investigate the role of a specific receptor, GPR183, in these immune cells and how it influences their behavior in the tumor environment. By targeting this mechanism, the research seeks to develop new therapeutic strategies that could enhance the effectiveness of existing treatments for glioblastoma.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that improve survival rates and quality of life for patients with glioblastoma.
How similar studies have gone: Previous research has shown promise in targeting immune cell reprogramming in various cancers, suggesting potential success for this novel approach in glioblastoma.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Chen, Peiwen — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Chen, Peiwen
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.